Lineage Cell Therapeutics (LCTX) grants 900,000 stock options to General Counsel

Rhea-AI Filing Summary

Samuel George A. III reported acquisition or exercise transactions in this Form 4 filing.

Lineage Cell Therapeutics, Inc. reported that its General Counsel and Secretary, Samuel George A. III, received a grant of 900,000 employee stock options on March 5, 2026. These options were awarded at no purchase price at grant as part of his compensation.

According to the vesting terms, one quarter of the options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments after that date, contingent on continuous employment each month.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Samuel George A. III

Role General Counsel and Secretary

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	900,000	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 900,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Samuel George A. III

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.84	03/05/2026		A		900,000		(1)	03/05/2036	Common Shares	900,000	$0	900,000	D

Explanation of Responses:

1. One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

	/s/ George A. Samuel III	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lineage Cell Therapeutics (LCTX) report for Samuel George A. III?

Lineage Cell Therapeutics reported that General Counsel and Secretary Samuel George A. III was granted 900,000 employee stock options. The options were awarded at no purchase price at grant and represent a compensation award rather than an open-market share purchase or sale.

When do the newly granted Lineage Cell Therapeutics (LCTX) stock options begin vesting?

The granted options begin vesting on March 5, 2027, when one quarter of the award vests. The remaining options then vest in 36 equal monthly installments thereafter, conditioned on the completion of each month of continuous employment with Lineage Cell Therapeutics.

How many stock options did Lineage Cell Therapeutics (LCTX) grant to its General Counsel?

Lineage Cell Therapeutics granted 900,000 employee stock options to its General Counsel and Secretary, Samuel George A. III. Following this award, he held a total of 900,000 derivative securities of this type, reflecting the full amount of the new grant in this filing.

Is the Lineage Cell Therapeutics (LCTX) Form 4 transaction a purchase or a grant?

The Form 4 transaction is a grant of stock options, not an open-market purchase. It is coded as a grant, award, or other acquisition, with 900,000 employee stock options awarded at no purchase price to the company’s General Counsel and Secretary.

What conditions affect vesting of the new Lineage Cell Therapeutics (LCTX) options?

Vesting of the options depends on continuous employment. One quarter vests on March 5, 2027, and the remaining portion vests in 36 monthly installments, each tied to completion of a month of ongoing service with Lineage Cell Therapeutics.